triazoles has been researched along with Acanthamoeba Meningoencephalitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abagyan, R; Aksenov, A; Calvet, CM; Debnath, A; Jennings, G; Luth, MR; McKerrow, JH; Nes, WD; Podust, LM; Zhou, W | 1 |
| Colon, BL; Guy, RK; Kyle, DE; Rice, CA | 1 |
2 other study(ies) available for triazoles and Acanthamoeba Meningoencephalitis
| Article | Year |
|---|---|
CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).
Topics: 14-alpha Demethylase Inhibitors; Amebicides; Animals; Antifungal Agents; Cell Proliferation; Central Nervous System Protozoal Infections; Disease Models, Animal; Drug Repositioning; Humans; Microscopy, Electron, Transmission; Naegleria fowleri; Nitriles; Pyridines; Sterol 14-Demethylase; Sterols; Triazoles; Trophozoites | 2017 |
Phenotypic Screens Reveal Posaconazole as a Rapidly Acting Amebicidal Combination Partner for Treatment of Primary Amoebic Meningoencephalitis.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Azithromycin; Central Nervous System Protozoal Infections; Disease Models, Animal; Drug Combinations; Drug Discovery; Drug Synergism; Female; Fluconazole; Humans; Inhibitory Concentration 50; Mice; Naegleria fowleri; Phenotype; Time Factors; Triazoles; United States; United States Food and Drug Administration | 2019 |